High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS- CoV-2) in sub-Saharan Africa by Tso, For Yue et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Virology Papers Virology, Nebraska Center for 
2021 
High prevalence of pre-existing serological cross-reactivity 
against severe acute respiratory syndrome coronavirus-2 (SARS- 
CoV-2) in sub-Saharan Africa 
For Yue Tso 
Salum Lidenge 
Phoebe B. Peña 
Ashley A. Clegg 
John R. Ngowi 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/virologypub 
 Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Cell and Developmental 
Biology Commons, Genetics and Genomics Commons, Infectious Disease Commons, Medical 
Immunology Commons, Medical Pathology Commons, and the Virology Commons 
This Article is brought to you for free and open access by the Virology, Nebraska Center for at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an 
authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
For Yue Tso, Salum Lidenge, Phoebe B. Peña, Ashley A. Clegg, John R. Ngowi, Julius Mwaiselage, Owen 
Ngalamika, Peter Julius, John T. West, and Charles Wood 
High prevalence of pre-existing serological cross-reactivity
against severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) in sub-Saharan Africa
For Yue Tsoa,b, Salum J. Lidengea,b,d,e, Phoebe B. Peñaa,b, Ashley A. Clegga,b,
John R. Ngowid, Julius Mwaiselaged,e, Owen Ngalamikaf, Peter Juliusg, John T. Westa,c,
Charles Wooda,b,c,*
aNebraska Center for Virology, Lincoln, NE, USA
b School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA
cDepartment of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA
dOcean Road Cancer Institute, Dar es Salaam, Tanzania
eMuhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
fDermatology and Venereology Section, University Teaching Hospitals, University of Zambia School of Medicine, Lusaka, Zambia
gDepartment of Pathology and Microbiology, University of Zambia School of Medicine, Lusaka, Zambia
A R T I C L E I N F O
Article history:
Received 1 October 2020
Received in revised form 27 October 2020










A B S T R A C T
Objective: Significant morbidity and mortality have occurred in the USA, Europe, and Asia due to severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2), whereas the numbers of infections and deaths
in sub-Saharan Africa (SSA) have remained comparatively low. It has been hypothesized that exposure of
the population in SSA to other coronaviruses prior to the COVID-19 pandemic resulted in some degree of
cross-protection against SARS-CoV-2 infection and pathogenesis. We evaluated this hypothesis by
comparing SARS-CoV-2 cross-reactive antibodies in pre-pandemic plasma samples collected from SSA
and the USA.
Method: Pre-COVID-19 pandemic plasma samples from SSA and the USA were collected and tested by
immunofluorescence assay against the spike and nucleocapsid proteins of all known human
coronaviruses (HCoVs).
Results: The prevalence of SARS-CoV-2 serological cross-reactivity was significantly higher in samples
from SSA compared with the USA. Most of these cross-reactive samples cross-recognized the SARS-CoV-2
nucleocapsid protein and the spike proteins of other HCoVs. Nucleocapsid proteins from HCoV-NL63 and
HCoV-229E were detected in most samples, thereby implicating prior exposure to these two HCoVs as the
likely source of cross-reactive antibodies against SARS-CoV-2.
Conclusion: The low incidences of SARS-CoV-2 infection and disease in SSA appear to be correlated with
the pre-pandemic serological cross-recognition of HCoVs, which are substantially more prevalent in SSA
than the USA.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
The first case of the COVID-19 pandemic was reported in late
2019 in Wuhan, China, and its causative agent the severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) subsequently
spread rapidly worldwide (Lu et al., 2020). SARS-CoV-2 is a
betacoronavirus and a close relative of the original SARS and
Middle East respiratory syndrome coronavirus (MERS) which both
cause lethal diseases in human (Chen et al., 2020; Gussow et al.,
2020). Four other less pathogenic human coronaviruses (HCoVs)
comprising HCoV-OC43, HCoV-HKU-1, HCoV-NL63, and HCoV-
229E cause mild upper respiratory tract diseases referred to as the
“common cold” (Chen et al., 2020; Gussow et al., 2020).
At the time of writing, the COVID-19 pandemic has resulted in
over 31 million confirmed SARS-CoV-2 infections and nearly a
million deaths, with about 22% of the confirmed cases and 21% of
the confirmed deaths occurring in the USA (Nuzzo et al., 2020).
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Several factors support the hypothesis that populations in sub-
Saharan Africa (SSA) might be more susceptible to coronaviral
infection and disease, including the high infectious disease burden
(Ebola, yellow fever, and cholera outbreaks, as well as high
endemic prevalence of HIV-1, tuberculosis, malaria, and parasitic
diseases), numerous socioeconomic factors, poor hygiene, nutri-
tional deficiency, and lack of health care access in rural areas
(Oleribe et al., 2015; Semeere et al., 2016). The infrastructure for
diagnostics and epidemiological surveillance is suboptimal in
Africa, but the COVID-19 case mortality rates are lower where large
scale testing has been possible compared with elsewhere in the
world. There have been no reports from SSA of any abnormal
increases in the numbers of respiratory diseases or deaths, which
are the hallmarks of the COVID-19 pandemic. Despite the high
number of COVID-19 cases and mortality in the USA, Europe, and
Asia, the COVID-19 disease burden has remained surprisingly low
in SSA (Nuzzo et al., 2020). A potential explanatory factor could be
the relatively younger African populations compared with those in
the USA or Europe, which may have resulted in more asymptom-
atic cases (Gaye et al., 2020). In addition, the onerous high
infectious disease burden in SSA may have included exposure to
other HCoVs, which could have elicited humoral responses against
conserved epitopes among coronaviruses to engender cross-
protection. This prior exposure to other coronaviruses may offer
some level of cross-protective immune response against SARS-
CoV-2 infection, thereby reducing the number and/or severity of
COVID-19 cases.
To investigate this hypothesis, we examined pre-COVID-19
pandemic plasma samples from Tanzania, Zambia, and the USA to
determine their serological cross-reactivity against the spike and
nucleocapsid proteins of SARS-CoV-2 and other HCoVs (SARS,
MERS, HCoV-OC43, HCoV-HKU-1, HCoV-NL63, and HCoV-229E), as
well as whether HIV-1 infection, which is endemic in SSA, might
affect the prevalence of serological cross-reactive against SARS-
CoV-2. We found that pre-COVID-19 pandemic SSA samples had a
significantly higher prevalence of serological cross-reactivity
against SARS-CoV-2 than samples from the USA. In addition, the
SARS-CoV-2 cross-reactive plasma samples strongly recognized
the spike and nucleocapsid proteins from specific human seasonal
coronaviruses, thereby suggesting that prior exposure to these
other coronaviruses may have induced partially protective
responses against SAR-CoV-2.
Materials and methods
Study cohort and samples
The study cohort comprised 289 consenting subjects aged 18
years and belonging to both genders from Dar es Salaam, Tanzania;
Lusaka, Zambia; and Lincoln, Nebraska, USA. The Tanzanian
samples comprised 105 plasma samples collected from voluntary
blood donors between March and May, 2019. The Zambian samples
comprised 99 plasma samples collected between 2017 and early
2019. The plasma samples from the USA were collected from 85
blood donors during 2005, 2007, and 2009 in Lincoln, Nebraska,
and they were also evaluated for comparison. All study procedures
were approved by the Institutional Review Boards at the Tanzania
National Institute for Medical Research, Ocean Road Cancer
Institute, University of Zambia Biomedical Research Ethics
Committee, and the University of Nebraska-Lincoln.
HIV serological testing
HIV-1 serology testing was conducted using the HIV Rapid Test
Algorithm (United Republic of Tanzania, 2007) in Tanzania and the
Alere Determine HIV-1/2 Ag/Ab Combo test in Zambia (Abbott
Laboratories, Chicago, IL, USA). The serological results were
verified in our laboratory at Lincoln, Nebraska using the HIV-1-
2.0 First Response kit (Premier Medical Corporation Limited,
Daman, India).
Immunofluorescence assay (IFA) against SARS-CoV-2 and other HCoVs
To detect the presence of serological cross-reactivity against
SARS-CoV-2 and other HCoVs, we used an IFA against the spike and
nucleocapsid proteins of SARS, SARS-CoV-2, MERS, HCoV-OC43,
HCoV-HKU-1, HCoV-NL63, and HCoV-229E. Briefly, HEK-293T cells
(American Type Culture Collection [ATCC], Manassas, VA, USA)
were transfected with mammalian expression plasmids encoding
either the spike or nucleocapsid proteins of the respective
coronaviruses (Addgene, Watertown, MA, USA and Sino Biological,
Wayne, PA, USA). After 48 h, the transfected cells were fixed and
seeded onto 12-well polytetrafluoroethylene printed slides
(Electron Microscopy Sciences, Hatfield, PA, USA), where each
well contained either spike, nucleocapsid, or mock transfected
cells, before permeabilization with 0.3% hydrogen peroxide (H2O2)
methanol solution. The prepared IFA slides were stored at 80 C.
Plasma samples were diluted 1:20 with phosphate-buffered
saline (PBS) plus 0.1% Tween-20 and incubated at room tempera-
ture for 30 min. The prepared IFA slides were thawed and
incubated with PBS plus 0.1% Tween-20 for 30 min at 37 C. Each
diluted plasma sample was then added to cells expressing each
HCoV antigen or control wells and incubated for 1 h at 37 C. After
primary antibody binding and washing, a secondary mouse
monoclonal anti-human immunoglobulin G (IgG) antibody (ATCC,
USA) was bound for 1 h at 37 C, before washing to remove any
excess unbound antibody. Tertiary CY2-conjugated donkey anti-
mouse IgG (Jackson Immunoresearch Laboratories, West Grove, PA,
USA) was then added and incubated for 1 h at 37 C. Finally, the
slides were counterstained with 0.004% Evans blue solution for
30 s. All IFA slides were washed 3 times with PBS after each
incubation step. The stained IFA slides were read by three
independent readers using a Nikon Eclipse 50i fluorescence
microscope. Positive cells were enumerated based on green
fluorescence against a red cellular counterstain. A well was only
considered positive or negative if at least two independent readers
were concordant in reporting the outcome. Summarization of
results and statistical analysis (two-tailed Fisher’s exact test) were
conducted and plotted using GraphPad (GraphPad Software, San
Diego, CA, USA).
Results
To evaluate the serological cross-reactivity against SARS-CoV-2
and other HCoVs, we obtained blood donor plasma samples from
Tanzania (n = 105), Zambia (n = 99), and the USA (n = 85) (Table 1).
These samples were collected between 2005 and May 2019, and
before the current COVID-19 pandemic, but synchronous plasma
samples were not available due to the retrospective nature of the
study. Among our cohort, 6.7% and 43.4% of the Tanzanian and
Zambian samples, respectively, were HIV-1 positive. By contrast,
all of the plasma samples collected in the USA were HIV-1 negative.
The high prevalence of HIV-1 infection in the Zambian samples
does not reflect the national HIV-1 infection rate, but instead it was
Table 1
Study cohort and sampling time periods.
Country Sample size HIV-1 positive (%) Sampling time period
Tanzania 105 7 (6.7%) March to May 2019
Zambia 99 43 (43.4%) 2017 to early 2019
USA 85 0 (0%) 2005, 2007, and 2009
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intended to support comparisons of the cross-reactivity against
SARS-CoV-2 and the recognition of other coronaviruses in HIV-1
positive and negative subjects.
The plasma samples were screened for cross-reactivity against
SARS-CoV-2 using an IFA. As shown in Figure 1, COVID-19
convalescent positive control plasma resulted in strong green
fluorescence staining in cells expressing either the SARS-CoV-2
spike or nucleocapsid proteins, but not in the mock transfected
cells. Green fluorescence was not evident on antigen-expressing
cells stained with negative control plasma, thereby demonstrating
the specificity of the IFA for detecting SARS-CoV-2 specific IgG
antibodies. Interestingly, green fluorescence was evident on cells
expressing either the SARS-CoV-2 spike or nucleocapsid proteins
when stained with some pre-COVID-19 pandemic plasma samples,
which indicates the presence of antibodies cross-reactive against
SARS-CoV-2 prior to the current COVID-19 pandemic (Figure 1).
Compared with samples from the USA (2.4%), the prevalence of
serological cross-reactivity against SARS-CoV-2 was significantly
higher in Tanzania (19%) (P = 0.0002) and Zambia (14.1%) (P =
0.0069) (Figure 2A). A breakdown of the anti-SARS-CoV-2 cross-
reactivity indicated that most of the Tanzanian and Zambian cross-
reactive responses targeted the SARS-CoV-2 nucleocapsid protein,
with 17.1% (P = 0.0001) and 13.1% (P = 0.0018), respectively, and
these levels were significantly higher than those in samples from
the USA, i.e., 1.2% (Figure 2B). There were no statistical differences
in the anti-SARS-CoV-2 spike cross-reactivity prevalence rates,
with 2.9% in Tanzania, 4% in Zambia, and 1.2% in the USA (Figure
2C). In addition, none of the cross-reactive samples from Tanzania
were HIV-1 positive and only 5/43 (11.6%) HIV-1 positive samples
from Zambia were cross-reactive toward SARS-CoV-2. Moreover, 9/
56 (16%) HIV-1 negative samples from Zambia were cross-reactive
toward SARS-CoV-2. Therefore, HIV-1 infected individuals
appeared to have a lower cross-reactive response toward SARS-
CoV-2. However, an HIV-1 positive cohort with a larger sample size
will be needed to verify this observation.
To investigate whether anti-SARS-CoV-2 cross-reactivity corre-
lated with past exposure to other HCoVs, pre-COVID-19 pandemic
plasma samples that cross-reacted against SARS-CoV-2 were
Figure 1. IFA against either mock, SARS-CoV-2 spike, or nucleocapsid expressing cells. Representative images are shown for IFA with negative control plasma, COVID-19
convalescence plasma (positive control), and pre-COVID-19 pandemic cross-reactive plasma samples 21928 and 21933. Sample 21928 exhibited cross-reactivity against SARS-
CoV-2 spike, but not its respective mock and SARS-CoV-2 nucleocapsid. Sample 21933 exhibited cross-reactivity against SARS-CoV-2 nucleocapsid, but not its respective mock
and SARS-CoV-2 spike. White arrows indicate positive cells. Scale bar represent 50 mm.
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tested to determine their anti-HCoV responses. As demonstrated
by a representative cross-reactive plasma sample (21854), IFA
against the spike and nucleocapsid proteins of different HCoVs
detected IgG antibodies against the HCoV-OC43, HKU-1, NL63, and
229E spike proteins (Figure 3). However, the same plasma sample
only recognized the nucleocapsid of HCoV-NL63, which suggests
that HCoV-NL63 was the main source of antigenic exposure for this
individual. When we analyzed all of the SARS-CoV-2 serologically
cross-reactive samples, we found that 100% recognized the spike
proteins from all four HCoVs that cause the common cold, but not
those from SARS and MERS (Figure 4A). This difference in the
recognition of the common HCoV spike proteins versus the SARS
and MERS spike proteins was statistically significant (P < 0.0001).
In addition, comparisons of HCoV nucleocapsid recognition among
all of the samples showed that the most commonly recognized
nucleocapsid was that of HCoV-NL63, followed by HCoV-229E,
with 92% and 50%, respectively (Figure 4B). This difference was
statistically significant compared with the recognition of the other
HCoVs, with P-values ranging from <0.0001 to 0.0002 for HCoV-
NL63, and P-values ranging from 0.0002 to 0.0054 for HCoV-229E
(Figure 4B). Finally, we compared how individuals from different
countries responded against various HCoV nucleocapsid proteins.
Qualitative analysis showed that the Zambian SARS-CoV-2 cross-
reactive samples tended to recognize a wider range of HCoVs
compared with the samples from Tanzania (Table 2). Some
Zambian individuals recognized four to six different HCoVs,
whereas Tanzanian individuals recognized a maximum of three
different HCoVs. However, the small sample size limited the
statistical analysis of this difference.
Discussion
Despite the rapid spread of SARS-CoV-2, which has caused
nearly a million deaths worldwide to date, the SARS-CoV-2 burden
remains surprisingly low in SSA. This is particularly surprising
given the high prevalence of other diseases such as HIV-1, malaria,
cancer, and tuberculosis, as well as inadequate health care and the
impact of poverty. The current SARS-CoV-2 disease burden is much
higher in the USA than countries in SSA. It is not known whether
the low prevalence of serological cross-reactivity to HCoV in the
USA, as shown in the present study, is directly associated with the
outcomes of the COVID-19 pandemic in the USA. Our data suggest
that populations in SSA were previously exposed to a spectrum of
HCoVs, which provided some cross-reactivity against SARS-CoV-2
and this may have limited the number of infections or pathogene-
sis in SSA. In support of this hypothesis, we detected serological
cross-reactivity against SARS-CoV-2 antigens in pre-COVID-19
plasma samples from Tanzania and Zambia at levels nearly 8 and 6
times higher, respectively, than the prevalence in samples from the
USA. By comparing the prevalence of serological cross-reactivity
against SARS-CoV-2 between HIV-1 positive and negative Zambian
individuals, we also found that HIV-1 infection appeared to lower
the cross-reactive response toward SARS-CoV-2, which could have
been due to a weakened immune response in HIV-1 infected
individuals. However, an HIV-1 positive cohort with a larger
sample size will be needed to confirm this observation.
Individuals in our study cohort who reacted to SARS-CoV-2
antigens predominantly cross-reacted with the SARS-CoV-2
nucleocapsid protein. Consistent with spike protein variation
across coronaviruses, few individuals reacted with the SARS-CoV-2
spike protein. This also supported the indication that the SARS-
CoV-2 spike protein is a more specific target for serological testing
of SARS-CoV-2 infection and the humoral response to infection.
Conversely, a recent study suggested that the SARS-CoV-2
nucleocapsid is more sensitive than the spike protein for the early
detection of SARS-CoV-2 infection (Burbelo et al., 2020), thereby
highlighting the distinction between sensitivity and specificity.
The results obtained based on our analysis of pre-COVID-19
pandemic samples support the hypothesis that detecting SARS-
CoV-2 infection with the nucleocapsid may generate a significant
number of false positive results, which could be country specific,
with countries such as Tanzania and Zambia potentially having
higher false positive rates than the USA due to prior exposure to
other coronaviruses.
We also investigated which HCoV was responsible for the
observed cross-reactivity with SARS-CoV-2 and found that all
SARS-CoV-2 cross-reactive samples strongly cross-reacted with
the spike proteins from HCoV-OC43, HCoV-HKU-1, HCoV-NL63,
Figure 2. Percentage prevalence of serological cross-reactivity against SARS-CoV-2
in Tanzania, Zambia, and the USA. (A) Combined serological cross-reactivity against
SARS-CoV-2 spike and nucleocapsid. (B) Serological cross-reactivity against SARS-
CoV-2 nucleocapsid. (C) Serological cross-reactivity against SARS-CoV-2 spike.
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Figure 3. IFA against SARS, MERS, HCoV-OC43, HCoV-HKU-1, HCoV-NL63, and HCoV-229E spike or nucleocapsid expressing cells. Representative images are shown of IFA
with pre-COVID-19 pandemic cross-reactive plasma sample 21854. Sample 21854 strongly recognized the spike proteins of HCoV-OC43, HCoV-HKU-1, HCoV-NL63, and
HCoV-229E, but not those of SARS and MERS. Sample 21854 only recognized the nucleocapsid of HCoV-NL63 but not those of the other human coronaviruses. White arrows
indicate positive cells. Scale bar represent 50 mm.
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and HCoV-229E, but not those from SARS or MERS. These findings
suggest that some immunogenic epitopes within the spike protein
may be shared among all known HCoVs. In addition, most of our
SARS-CoV-2 cross-reactive samples reacted strongly against the
nucleocapsid proteins of HCoV-NL63 and HCoV-229E, thereby
suggesting that these two HCoVs may have served as the source of
antigenic exposure in SSA prior to the COVID-19 pandemic. Cross-
reactivity against SARS-CoV-1 nucleocapsid as a result of exposure
to HCoVs, such as HCoV-OC43, has been reported previously
(Patrick et al., 2006), but the present study is the first to link HCoV-
NL63 and HCoV-229E to cross-reactivity against SARS-CoV-2 in the
SSA.
HCoV-NL63 and HCoV-229E are alphacoronaviruses, whereas
HCoV-OC43 and HCoV-HKU-1 are betacoronaviruses like SARS-
CoV-2 (Abdul-Rasool and Fielding, 2010). In addition, HCoV-NL63
is the only other HCoV that uses angiotensin-converting enzyme 2,
which is the same receptor used by SARS and SARS-CoV-2 (Abdul-
Rasool and Fielding, 2010; Hofmann et al., 2005). The epidemiology
of HCoV-NL63 and HCoV-229E is poorly defined in adults. Some
studies reported a prevalence rate of 8.8% for HCoV-NL63 in the
USA but less than 1% in the UK (Esper et al., 2005; Gaunt et al.,
2010). The prevalence of HCoV-229E is unclear. Importantly, no
epidemiological data exist for these two HCoVs in SSA. A recent
bioinformatics study also suggested that SARS-CoV-2 evolved from
a bat coronavirus and bats may be a primary reservoir (Boni et al.,
2020). Given the abundant wildlife in Africa, including multiple
species of bats, and their often close proximity to humans, we
cannot exclude the possibility of exposure to zoonotic coronavi-
ruses eliciting the observed cross-reactivity against SARS-CoV-2
and other HCoVs. Our results suggest that infections with HCoV-
NL63 or similar transmissible zoonotic agents were common in
SSA prior to the COVID-19 pandemic.
Finally, the functions of these SARS-CoV-2 cross-reactive
antibodies and whether they provide any protection against
SARS-CoV-2 infection or disease progression is still unclear, and
these questions cannot be resolved with retrospective cross-
sectional sampling. The SARS-CoV-2 nucleocapsid is the major
antigen recognized by these cross-reactive antibodies, so we
suggest that antibody-dependent effector mechanisms such as
antibody-dependent cellular cytotoxicity could play protective
roles. Our detection of SARS-CoV-2 cross-reactive antibodies in
pre-COVID-19 pandemic samples supports the finding obtained in
a recent study, which showed that exposure to HCoV/common cold
induced SARS-CoV-2 cross-reactive T-cell responses in pre-
pandemic samples (Mateus et al., 2020). Both adaptive responses
may have offered some protection against COVID-19 pathogenesis
if not SARS-CoV-2 infection. A limitation of our study is that no
peripheral blood mononuclear cells were collected prior to the
COVID-19 pandemic in order to analyze the potential cross-
reactive T-cell response. Thus, a larger sample size and more in-
depth longitudinal analysis of the functions of these cross-reactive
Figure 4. Percentage prevalence of serological cross-reactivity against SARS, MERS,
HCoV-OC43, HCoV-HKU-1, HCoV-NL63, and HCoV-229E. (A) Spike. (B) Nucleocap-
sid.
Table 2
Individual cross-reactive responses against the nucleocapsid proteins of SARS,
MERS, HCoV-OC43, HCoV-HKU-1, HCoV-NL63, and HCoV-229E.
Country Sample ID SARS MERS OC43 HKU-1 NL63 229E
Tanzania 21850 – – – – + –
Tanzania 21854 – – – – + –
Tanzania 21868 – – – – + +
Tanzania 21872 – – – – + +
Tanzania 21873 – – – – + –
Tanzania 21928 – – – – + –
Tanzania 21933 – – – – + –
Tanzania 211141 + – – – + +
Tanzania 211145 – – – – + +
Tanzania 211157 – – – + + +
Tanzania 211176 + – – – + –
Tanzania 211177 – – – – + –
Tanzania 211181 – – – – + +
Tanzania 211182 – – – – + –
Tanzania 211185 – – – + + +
Tanzania 211188 – – – – + +
Tanzania 211192 – + – – + +
Tanzania 211203 – – – – + +
Tanzania 211205 – – – – + +
Tanzania 211210 – – – – + +
Zambia C3076 + – – – + –
Zambia C3082 – – – – + –
Zambia C3154 – – – – + –
Zambia C3155 + – + + + +
Zambia C3156 – – – – + +
Zambia C3163 + – + – + +
Zambia C3166 – + – – + –
Zambia C3182 + – + + + +
Zambia C3187 – – – – – –
Zambia C3197 – – – – + –
Zambia C3202 + + + + + +
Zambia C3204 + + – – – –
Zambia N044 + – – – + –
Zambia N216 + – – – + –
USA KC-34 – – – – + +
USA KC-65 – – – – + +
HCoV, human coronaviruses; MERS, Middle East respiratory syndrome coronavirus;
SARS, severe acute respiratory syndrome coronavirus-2.
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antibodies, as well as the cross-reactive T-cell response will be
needed in future studies.
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